Same drug. New shape. Big difference for patients.

China's NMPA just approved a tablet version of selpercatinib (Retevmo) — the world's first highly selective RET inhibitor with CNS activity — expanding on its 2022 capsule approval. 🧪

#RETfusion #LungCancer #ThyroidCancer #DrugApproval

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells

🔦 buff.ly/wj2wwUX

@EmilianoCocco2 #NSCLC #RETfusion #FusionProtein